Valencia Technologies Corporation
$5.4M 473 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pacira Pharmaceuticals Incorporated
Pacira Pharmaceuticals Incorporated reported $5,371,375.94 across General Payments, Research, and Ownership to 18,305 physicians and teaching hospitals across 18,450 transactions.
- $5.4M Top quartile payer
- All-tracks total
- 18,450 Top 10% volume
- Transactions
- 18,305 Top 10% reach
- Recipients
- −$808.4K
- General Payments vs PY2023
Pacira Pharmaceuticals Incorporated reported $5,371,375.94 across all CMS Open Payments tracks (General + Research + Ownership) to 18,305 physicians and teaching hospitals in Program Year 2024 - ranking #262 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $4,792,036.39, averaging $293.44 per recipient.
How Pacira Pharmaceuticals Incorporated's $5.4M all-tracks total breaks down
Pacira Pharmaceuticals Incorporated's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
90/100
Total payments
D
60/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pacira-pharmaceuticals-incorporated Pacira Pharmaceuticals Incorporated
$5.4M · #262/1,925 · 0.0% industry · PY2024
- TOT $5.4M
- RANK #262
- SHARE 0.0%
- TXN 18,450
- RCP 18,305
- CAT 9
- GEN $4.8M
- ΔGEN −$808.4K
- TOP1 5.8%
- PY 2024
Volume peers
Nearest volume peer: Valencia Technologies Corporation ($5.4M)
Pacira Pharmaceuticals Incorporated sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pacira Pharmaceuticals Incorporated's CMS-reported General Payments decreased by $808.4K (−14.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PACIRA PHARMACEUTICALS INCORPORATEDPY2023: PACIRA PHARMACEUTICALS INCORPORATEDPY2024: Pacira Pharmaceuticals Incorporated. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $5,600,440.44
- PY2024
- $4,792,036.39
What the Data Shows for Pacira Pharmaceuticals Incorporated
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Pacira Pharmaceuticals Incorporated, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 9-category general-payment breakdown below at $2.3M (48.0% of General Payments, 638 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Pacira Pharmaceuticals Incorporated's 9-category general-payment breakdown at $2.3M, 48.0% of the reported total.
Pacira Pharmaceuticals Incorporated reports 9 general-payment categories - the top three are Consulting Fee (48.0%), Honoraria (16.6%), and Travel and Lodging (13.6%). The remaining 6 categories make up 21.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Pacira Pharmaceuticals Incorporated files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Pacira Pharmaceuticals Incorporated divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.3M | 638 | 48.0% |
| Honoraria | $795.8K | 234 | 16.6% |
| Travel and Lodging | $653.5K | 2,613 | 13.6% |
| Food and Beverage | $539.2K | 14,780 | 11.3% |
| Compensation for Faculty or Speaker (Medical Education) | $383.9K | 7 | 8.0% |
| Space Rental or Facility Fees | $43.4K | 12 | 0.9% |
| Education | $30.0K | 1 | 0.6% |
| Grant | $25.3K | 6 | 0.5% |
| Long-Term Medical Supply or Device Loan | $19.3K | 14 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $995,699.28 (20.8%) of $4,792,036.39 in this company's General Payments records across 10,697 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pacira Pharmaceuticals Incorporated
The five named recipients with the highest reported General Payments from this company
- 1
Mark Kronenfeld
$277,850.44 across 20 reported transactions
- 2
Christopher Paul Varacallo
$197,247.60 across 134 reported transactions
- 3
Mark Froimson
$189,594.61 across 19 reported transactions
- 4
Jeffrey Gadsden
$169,085.53 across 134 reported transactions
- 5
Karina Gritsenko
$161,921.10 across 186 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pacira Pharmaceuticals Incorporated ranks #262 of 1,925 by total payments (top 14% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,580 of 1,838 by HHI (bottom 14% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Cosette Pharmaceuticals Inc. : $1.1K total payments, HHI 183
- NeurAxis, Inc. : $12.9K total payments, HHI 182
- Mozarc Medical US LLC : $40.9K total payments, HHI 182
- Smoky Mountain Surgical Llc : $42.8K total payments, HHI 181
- Ascensia Diabetes Care Us Inc. : $258.2K total payments, HHI 181
- Conetic Solutions, Inc. : $36.7K total payments, HHI 180
- Pacira Pharmaceuticals Incorporated (this company) : $4.8M total payments, HHI 178
- Novo Nordisk AS : $2.4M total payments, HHI 178
- Omeza LLC : $1.5K total payments, HHI 178
- Caldera Medical, Inc : $117.1K total payments, HHI 177
- Karyopharm Therapeutics Inc. : $1.0M total payments, HHI 177
- Sagent Pharmaceuticals : $1.0K total payments, HHI 177
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pacira Pharmaceuticals Incorporated's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pacira Pharmaceuticals Incorporated.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pacira Pharmaceuticals Incorporated.
Showing 6 of 1,924 companies with CMS-reported payment data.
KLS-Martin L.P.
$5.3M 6,287 recipients
Compare payment profiles
SpringWorks Therapeutics, Inc.
$5.3M 4,420 recipients
Compare payment profiles
Olympus Corporation of the Americas
$5.2M 4,448 recipients
Compare payment profiles
Mitsubishi Tanabe Pharma America, Inc.
$5.2M 3,683 recipients
Compare payment profiles
BioXcel Therapeutics, Inc.
$5.2M 532 recipients
Compare payment profiles
Put this to use
Pacira Pharmaceuticals Incorporated ranks #262 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Pacira Pharmaceuticals Incorporated sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Pacira Pharmaceuticals Incorporated. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.